Clinical trials: Human Papillomavirus Virus
Papillomavirus Infections
Effect of Oral Papilozumib on Vaginal and Intestinal Microbiota in Human Papillomavirus (HPV)-Positive Women
This open-label, single-group study evaluated the effects of a 3-month oral synbiotic dietary supplement on vaginal and intestinal microbiota in women with a positive human papillomavirus (HPV) test.
- Trial name
- NCT07755566
- Testing
- Papilozumib
- Where
- Spain
- Volunteers
- 21 people
- Sponsor
- Hifas da Terra S.L.
Human Papilloma Virus
A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls
Cervical cancer is the most common cancer in women aged 15-44 years in East Africa, and mortality rates are very high. HPV vaccines are most effective if given to girls who have not yet acquired HPV infection.
- Trial name
- DoRIS (NCT02834637)
- Testing
- bivalent HPV vaccine, nonavalent HPV vaccine
- Where
- Tanzania
- Volunteers
- 930 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Cervical Intraepithelial Neoplasia
Recurrence in High-grade Lesions After Conization
Objectives: To identify factors associated with disease recurrence in patients with high-grade cervical intra-epithelial neoplasia (CIN) undergoing large loop excision of the transformation zone (LLETZ).
- Trial name
- NCT02540421
- Where
- Brazil
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Faculdade de Medicina do ABC
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)
A-007 is an investigational therapy which may be effective in the treatment of pre-cancerous cervical dysplasia (abnormal cell growth).
- Trial name
- TG-003 (NCT00596258)
- Testing
- A-007
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Tigris Pharmaceuticals
Carcinoma, Squamous Cell, Head and Neck Neoplasms
De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
The purpose of this research study is to learn about the effectiveness of using lower-intensity radiation and chemotherapy to treat human papillomavirus (HPV) associated low-risk oropharyngeal and/or unknown primary squamous cell…
- Conditions
- Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
- Trial name
- NCT02281955
- Testing
- Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation
- Where
- 5 sites in United States
- Volunteers
- 115 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Papillomavirus Infections, Genital Diseases, Female
Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)
This study was conducted in 2 parts. Part A was a randomized, double-blind, placebo-controlled, multicenter, sequential dose-escalating evaluation.
- Trial name
- NCT00365716
- Testing
- Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20, Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40, Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80
- Volunteers
- 1,158 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Precancerous Cervical Lesion
Role of Methylation Test Triage in HPV Positive Women
The pathological results were used as the gold standard in this study and the investigators analyze the diagnostic value of six gene methylation status (ASTN1 DLX1, ITGA4, RXFP3, SOX17, ZNF671) in triaging high-risk human…
- Trial name
- MTTRIHPW (NCT06366516)
- Testing
- Methylation Test
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Obstetrics & Gynecology Hospital of Fudan University
Vaccine, Human Papilloma Virus
HPV Message Testing and Social Media Campaign
This project involves a social media campaign to increase parent's knowledge and acceptance of the HPV (human papillomavirus) vaccine.
- Trial name
- NCT03747302
- Testing
- Social Media Message about HPV and HPV vaccine, Social media message about risk of electronic cigarettes.
- Where
- United States
- Volunteers
- 1,043 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Human Papillomavirus Infection
Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka
This PMS study aims to collect safety and reactogenicity data of Cervarix in the local population as per the licensing requirement of the Sri Lankan regulatory authority.
- Trial name
- NCT01551537
- Testing
- Cervarix data collection, Data Collection
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Head and Neck Cancer
Investigation of the Role of Human Papilloma Virus (HPV) in the Prognosis of Head and Neck Cancer
Human papilloma virus (HPV) is a recognised cause of some head and neck cancers. Important questions remain however, regarding the role of specific types of HPV, their effect on prognosis and different subtypes of oral…
- Trial name
- ARCAGE-NWE (NCT02049177)
- Where
- 6 sites in United Kingdom
- Volunteers
- 141 people
- Sponsor
- University of Aberdeen
EBV, HSV
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
Background: Infections caused by viruses are common causes of illnesses: the common cold, many ear infections, sore throats, chicken pox, and the flu are caused by different viruses.
- Conditions
- EBV, HSV, VZV, HPV
- Trial name
- NCT01011712
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Vulvar Intraepithelial Neoplasia, Genital Warts
SR-T100 Gel Efficacy & Safety Study for Vulva Pre-cancerous Lesions & Cutaneous Condyloma
This pilot clinical study is to evaluate the efficacy \& safety of SR-T100 gel (2.3% of SM in Solanum undatum plant extract) in patients with VIN(s) or EGW(s).
- Trial name
- NCT01676792
- Testing
- SR-T100 gel with 2.3% of SM in Solanum undatum plant extract
- Where
- Taiwan
- Volunteers
- 29 people
- Sponsor
- National Cheng-Kung University Hospital
Infections, Papillomavirus
The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
This extension study is designed to assess the safety of GSK Biological's HPV vaccine GSK580299 in female subjects who took part in the primary study NCT00294047 and received the control vaccine in countries for which the…
- Trial name
- NCT01249365
- Testing
- GSK580299 (Cervarix)
- Where
- 15 sites in Australia, Portugal and 2 more
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer, Genital Warts
Alternate Dosing Schedules Study for HPV Vaccine
To determine if delayed dosing of recombinant human papillomavirus (HPV) quadrivalent (Types 6, 11, 16, and 18) vaccine in 9-18 year old girls elicits an equivalent immune response (geometric mean titers to HPV 6,11,16, and 18 as…
- Trial name
- ADS (NCT00862810)
- Testing
- Received HPV vaccine first, Received concomitant vaccines first
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Duke University
Cervical High Grade Squamous Intraepithelial Lesion, Cervical Intraepithelial Neoplasia Grade 2/3
Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment
Imiquimod is a good non-invasive treatment option for women with cervical high-grade squamous intraepithelial neoplasia (cHSIL), especially those with a possible (future) pregnancy wish.
- Conditions
- Cervical High Grade Squamous Intraepithelial Lesion, Cervical Intraepithelial Neoplasia Grade 2/3, CIN 2/3, Cervical Intraepithelial Neoplasia
- Trial name
- PRedICT-TOPIC (NCT05405270)
- Testing
- Imiquimod, 3x vaginal swab for microbiome analysis, Expectative management
- Where
- 15 sites in Netherlands
- Volunteers
- 410 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Infections, Papillomavirus, Papillomavirus Vaccines
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This Phase IV, observer-blind study is designed to evaluate the safety and immunogenicity of Cervarix in HIV infected…
- Trial name
- NCT01031069
- Testing
- GSK Biologicals' HPV vaccine 580299, Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)
- Where
- 15 sites in Brazil, Estonia and 2 more
- Volunteers
- 873 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus, Infection
Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)
PROJECT JUSTIFICATION: Cervical cancer is a serious public health problem in Brazil, and is the cause of significant morbidity and mortality among Brazilian women.
- Trial name
- NCT01159834
- Volunteers
- 1,574 people, healthy volunteers welcome
- Sponsor
- Barretos Cancer Hospital
Human Papilloma Virus
SDH of HPV Vaccine Completion
The purpose of this research study is to find out which factors influence parents' ability to complete the human papillomavirus (HPV) vaccine series for their child.
- Trial name
- NCT03709602
- Where
- United States
- Volunteers
- 3,076 people
- Sponsor
- Duke University
Cervical Cancer Screening, p16 Protein
Immunohistochemical Staining of p16 for the Screening of Cervical Cancer
Cyclin kinase inhibitor P16INK4A has overexpression in cervical cancer, and hence becoming an alternative method for cervical cancer screening.
- Conditions
- Cervical Cancer Screening, p16 Protein, Cytology, High-risk Human Papillomavirus
- Trial name
- NCT04650711
- Testing
- p16 protein expression
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Lei Li
Human Papilloma Virus, Anal Squamous Cell Carcinoma
High Resolution Anuscopy Study
The majority of anal squamous cell carcinomas (SCC) stem from infection with high-risk human papillomavirus (HPV). Anal SCC is rare among the general population but affects several populations disproportionately.
- Trial name
- NCT06697964
- Testing
- HRA
- Where
- Belgium
- Volunteers
- 500 people
- Sponsor
- Universitair Ziekenhuis Brussel
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.